Health

European Commission seeks to intervene in Illumina’s acquisition of Grail

In an unusual step, the European Commission plans to intervene in the recent merger between Illumina (ILMN) and Grail because regulators were unable to finish reviewing the deal before it was completed, raising concerns that competition in the market for DNA sequencing tests will now be damaged.

The move comes one month after Illumina stunned regulators by announcing it had closed its $8 billion acquisition, even though the EC had opened an investigation only weeks earlier at the prompting of France and five other European Union member states. In the U.S., the Federal Trade Commission had already filed a complaint last March to block the deal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED



Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button